RJA
STOK icon

Raymond James & Associates’s Stoke Therapeutics STOK Stock Holding History

Raymond James & Associates’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,067
Closed -$252K – 4101
2020
Q4 		$252K Buy
+4,067
New +$186K ﹤0.01% 3240

Other funds holding STOK

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's STOK Position: Q1 2021 in Review

Raymond James & Associates sold out of Stoke Therapeutics (STOK) in Q1 2021, closing a stake of 4,067 shares — an estimated $252K sold.

Raymond James & Associates first reported a position in STOK in Q4 2020 and held it in 1 quarter. The position peaked at $252K in Q4 2020. 106 funds tracked by Wall St. Rank hold STOK as of Q1 2021.

  • Raymond James & Associates reported no remaining Stoke Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Raymond James & Associates sold 4,067 Stoke Therapeutics shares in Q1 2021, an estimated $252K.
  • Raymond James & Associates first reported a position in Stoke Therapeutics in Q4 2020 and held it in 1 quarter.
  • Raymond James & Associates's Stoke Therapeutics position peaked at $252K in Q4 2020.
  • 106 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2021.

Based on Raymond James & Associates's 13F filing for Q1 2021, filed 14 May 2021.